Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664176 | 0.79 | PTPN1 (0.54) | PTPN1GSK3BPDPK1MMP1CES2 | |
| SCHEMBL11158880 | 0.77 | PTPN1 (0.51) | PTPN1GSK3BPDPK1MMP1CES2 | |
| SCHEMBL133449 | 0.71 | PTPN1 (0.59) | PTPN1GSK3BPDPK1MMP1CES2 | |
| SCHEMBL19642328 | 0.71 | PDPK1 (0.65) | PTPN1GSK3BPDPK1MMP1CES2 | |
| SCHEMBL18860300 | 0.71 | PTPN1 (0.59) | PTPN1GSK3BPDPK1MMP1CES2 | |
| SCHEMBL7343509 | 0.69 | HDAC1 (0.57) | PTPN1GSK3BPDPK1MMP1CES2 | |
| SCHEMBL11780105 | 0.68 | PDPK1 (0.61) | PTPN1GSK3BPDPK1MMP1CES2 | |
| SCHEMBL7338185 | 0.68 | HDAC1 (0.60) | PTPN1GSK3BPDPK1MMP1CES2 | |
| SCHEMBL14364710 | 0.68 | GSK3B (0.47) | PTPN1GSK3BCES2CES1DPP4 | |
| SCHEMBL29987081 | 0.68 | PTPN1 (0.75) | PTPN1GSK3BPDPK1MMP1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| CN-101952275-B | Modulators for amyloid protein beta | HOFFMANN LA ROCHE | 2014-06-18 | — | — | CN | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| CN-101952275-A | Modulators for amyloid beta | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | PTPN1 4060/4885GSK3B 597/4885PDPK1 1452/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | PTPN1 4025/4885GSK3B 593/4885PDPK1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.